For joining us here at Guggenheim's Healthcare Innovation Conference. I'm really pleased to actually have Avalyn Pharma back with us again, but this year as a public company.
Woo-hoo.
Thrilled to have Lyn Baranowski, CEO, to my right, and to her right, Doug Carlson, CFO and Chief Business Officer. Thank you both for joining us.
Pleasure.
As always, an exciting time to be talking about IPF and biotech. Maybe just in terms of, just to kick us off, Lyn, maybe give us a quick background on Avalyn, what you're seeking to accomplish in IPF in particular.
Yeah, great. Thanks for the invitation and for being here to talk with us. Avalyn's a clinical-stage company. We're focused in pulmonary fibrosis. It is one of the rare deadly diseases in the lung space that just is massively unaddressed. What I mean by that is that we today have three drugs that are approved for the disease, two that have been on the market for about 10 years, and those two drugs are almost impossible for patients to tolerate. If you're on one of those two drugs or you're trying to be on one of those two drugs, you're going to have awful symptoms of the drug.
Horrible nausea and vomiting with one, horrible diarrhea with the other, and that's on top of the symptoms of this already quite horrible disease where you've got breathlessness, you've got cough, you can't get enough oxygen to get enough exercise capacity. Fundamentally, patients might try these oral medicines, but they cycle off medicine incredibly quickly because of the tolerability profile. What we're doing here at Avalyn is taking those same drugs that we know work, but now delivering them to the lung directly with an inhalation. When we do that, if you can imagine it, we're focusing our drug in the lung, which is the target organ, and we actually have better exposure in the lung, despite the fact that we're dropping the dose by more than tenfold as compared to the oral.
When you do that, you're also avoiding most of the systemic exposure that you'd have with the oral. We think this approach is much more sensible for patients because it takes the drugs that we know work, but now makes them significantly more tolerable, and we think more effective by delivering them to the lung directly. With that kind of profile, we now think it's going to be possible with these drugs, number one, to take patients that are diagnosed and treat them with these medicines, allow them to stay on medicine and benefit from the drugs now over a much longer term horizon. Fundamentally in this disease, we can talk about this, patients have been unable to combine mechanisms. We've learned in lung disease that we typically want to be combining different drugs together to do more for patients and their diseases.
That's impossible in this disease because each of the monotherapies is so impossible to tolerate. But resolving the tolerability with inhaled delivery allows us, we think, to help the market evolve in the algorithm towards one where we can start benefiting patients by dosing them in combination. We think that's going to be a massive change for this market. It's what the patients need, and I think we're the company to be able to deliver that.
Great. Let's talk about what is unique and novel about, I guess I'm saying the same thing twice, but what is unique about the approach with the device itself?
Not just the delivery program, but there's a choice of going after a nebulized product.
Yeah.
That I think is important.
Why, yeah. So when we think about delivering drugs to the lung with an inhalation, we obviously have to think about the drug itself and figure out how we can formulate it. Not all drugs are formulatable in all the different technologies that exist. We have to think about also the kind of particle size that we want to deliver. In this case, we want to deliver a really tiny particle that will get to the distal parts of the lung. The alveoli is the target tissue here. Not every nebulizer will be able to generate the right particle size to get there. Then we have to think about deeply the patients, and I think this is maybe what a lot of investors don't fully understand about this disease. These patients, as I said earlier, they're older, they're sick, they're frail, they have limited exercise capacity, they're breathless.
Some inhalers, like dry powder inhalers, require a patient to do this, which I can do because I've only got mild asthma. Normal asthmatic patients can do that, but this kind of patient isn't going to have that inhalation capacity. So our view is that this market and these patients are best served by figuring out an inhalation technology that the patients can actually dose. So this is a small handheld nebulizer. It's 510(k) approved. It's patent protected. We have a license to it. We have exclusivity in it in the molecules. The device is in our label. But from a patient perspective, this generates and delivers this really gentle mist. Sort of looks like if anyone ever had a humidifier when they were sick and their mom put it on when they were a kid.
It's very gentle and soft like that, and patients don't need to have any kind of a special breathing to be able to dose it. You just put it in your mouth and you breathe in and out using what we call tidal breathing, your normal breathing pattern.
Yeah.
Through that lens, we think it's actually something the patients can dose, which is really critical here, because if patients can't dose or they cough a drug right back out, you're not getting any drug on board.
Yeah. Got it. Then, just in terms of some of the unique characteristics of being able to get to the distal lung.
What scientifically have you done, what studies have you done or modeling have you done to show or suggest that the drug is getting where it needs to be?
Yeah, lots and lots. Fundamentally, when we look at exposure, we actually, in this disease, because it's a lung disease, we can actually look at lung exposure by doing a bronchoscopy, also called a bronchoalveolar lavage. We collect the bronchoalveolar lavage fluid, and then we can assess the difference in lung exposure between an inhalation versus an oral. That's how we know with both of these programs that we have better exposure in the lung because we've done that work.
The other important variable, as I mentioned earlier, is the particle size. Just making sure that with this aerosol and this device, we can get there. We did some really interesting work that we presented earlier this year at ERS, which is on our website, and we're happy to share it with anyone that's interested, around an in silico model looking at distribution to those tissues. We can see that even in severe IPF lungs, we get exquisite deposition into the alveoli, even in those injured lungs where there's a lot of fibrosis. It's again because of the science that we've built into the nebulizer and the particle size that's designed to get there.
Great. Let's go to the data itself.
Okay.
that we have so far. We've got MIST enrolled, but what informed it? In terms of the data, what informed the program and just what we have so far
In terms of the AP01 data set.
Sure.
With pirfenidone?
I'll say when I took this job about four years ago and did market research with doctors at the get-go, we were obviously testing, and I was interested to understand doctors' reaction to the efficacy and tolerability profile. I think it's really important to say just solving the tolerability problem with orals is a massive opportunity for us. Our goal number one with this program was just to demonstrate better tolerability. Having said that, the clinical data that we have suggests that we can not only improve the tolerability, but that we can improve the efficacy profile as well. We have historic data in IPF patients over one year, and we see in that data set what comes close to stabilization of lung function at one year. We then dosed two more cohorts in an open-label extension.
We see that same trend towards stabilization in each of the two additional cohorts. We then took patients from that program and put them into an open-label extension. We released five years' worth of data in IPF and about four in PPF, the two forms of the disease, and we see that same trend of stabilization over this long-term horizon, which I'm going to get excited about, Seamus, because I can't help it. It's remarkable because patients in that study were actually diagnosed with the disease two years before they started. So five years on drug, two years before they started, that's seven years into the course of their diagnosis, and they're still stable. Survival in this disease is typically three to five years. There's clearly a responder bias there in the five-year data. We're not here to suggest anything different.
But what's remarkable to me about the profile is that that five-year data doesn't exist on any oral drug or in the natural history.
Yeah.
The fact that we have any patient seven years into this diagnosis, which is a deadly one, is really exciting. It still gives me goosebumps. I'm such a nerd. But that to us is really promising because it speaks to the potential to keep patients on therapy, allowing them to benefit. And then finally, we have imaging data. This is an area that we can certainly talk about in the future, but imaging is kind of a new and exciting endpoint in our field. We actually can look at high-res chest CT scans. They're done routinely on diagnosis. We feed those into an AI algorithm that can then quantify how much fibrosis is in a patient's lung at any one point in time.
We've seen a demonstrable difference between patients at the high dose that we think is the right dose, and the change in time in their fibrosis level. And excitingly, that fibrosis quantification correlates with lung function. Said differently, if a patient is stable in their lung function, their fibrosis is stable. If a patient's lung function is improving, their fibrosis is decreasing. And it's really exciting to pick up that kind of correlation in that data set. All the data points that we have suggest that we're doing something demonstrably different. And our MIST study, which is the one that's ongoing now, we think will hopefully really give us powerful data to be able to move the program forward.
Great. Let's talk about AP02.
Before we go deeper into MIST. Differences between nintedanib and pirfenidone, and what right now nintedanib is the sort of dominant product
In market, although JASCAYD
JASCAYD's coming up.
Is launching like crazy.
Yeah, they're doing good.
Just in that context, what do you see as that sort of differential opportunity of AP01 versus AP02?
Yeah, it's a really interesting question. We've been able to look at the biomarkers of disease with each of the monotherapies, pirfenidone and nintedanib, and they are different in terms of how they work and on what biomarkers. We think there's additive effect actually, speaking to the potential to put them in combo, we think that's a really exciting idea. But honestly, Seamus, I think we're going to have to get the clinical data back from both programs. Both are in phase II right now, and I think that clinical data will help inform our thinking about the positioning of the two. There's some data, for example, with the pirfenidone program suggesting that pirfenidone and the imaging work may be playing a really strong role not only as an antifibrotic but also as an anti-inflammatory.
We're going to have to see if that observation holds in this next study, but if so, it may teach us where to kind of focus pirfenidone. I think nintedanib, similarly, we're going to have to learn from in terms of the clinical work to really then think about how to co-position. But fundamentally, they're both antifibrotics, but they work differently. I think there's certainly a role in this marketplace for both or the two together in combo.
Great. Talk to us about the answers that you're pursuing in the MIST study. What patient population you're going after, and also, what background therapy is likely to look like.
Yeah.
Walk us through the design and what you're hoping to see.
Sure, yeah. The MIST study that you mentioned is our AP01 inhaled pirfenidone phase II-B study, designed to be a 375-patient study, but we over-enrolled it. We completed enrollment ahead of schedule and then over-enrolled, so it's 398 patients in that study. We're doing it in the second indication in this space, which is called progressive pulmonary fibrosis, or PPF. The difference between IPF, which is idiopathic, and PPF is just the etiology. IPF, idiopathic. PPF is often driven by an underlying diagnosis. There's many diagnoses that will lead to PPF, but the one that we see most commonly in the clinical studies are typically autoimmune diseases. That's, for example, a patient that has systemic rheumatoid arthritis. Possibly because their RA drugs aren't adequately reaching their lung, they get an upregulation in an antigen and an inflammatory response in their lung.
That disease is called RA-ILD. It's an interstitial lung disease. Left unaddressed, that inflammation will progress into becoming fibrosis about 40% of the time. Once they become fibrotic, that's really where these drugs have a role. That's the difference in the disease. It's just etiology, but the pathophysiology is the same. We've learned to control for the difference in the rate of downward decline in lung function in PPF. We do that by picking patients with PPF to study that are analogous to IPF in terms of the rate of decline. We use some very special inclusion criteria that Boehringer Ingelheim created within the nintedanib program. When we do that, we literally see data across the two populations that's superimposable. That's kind of the trick to studying PPF correctly. Oral pirfenidone, we have data in PPF showing stabilization at one year.
There have been academic studies done of oral pirfenidone in PPF, and when I tell you they're academic studies, hopefully you know that means that they're designed sometimes with some unusual primary endpoints. Fortunately for us, all three of those academic studies collected office-based lung function data, and when you look at that office-based FVC data in the papers, you see an effect of the oral versus placebo in all three cases. Again, I think we've learned that they're the same fibrosis, it's just how to study them correctly. I think we're confident given the data we have and that historical data, that this will be a great opportunity for pirfenidone. Oral pirfenidone was never approved in PPF, so easier for us to study it clinically because, as you can imagine, we didn't have to exclude any patients who were on background oral pirfenidone.
From a commercial market access perspective, also easier to come to market because we don't have to worry about a step edit with an oral pirfenidone in that disease.
Yeah. In terms of just background therapy
Yeah.
There's the possibility of having patients who are in the study but progressing on nintedanib.
Correct.
What are some of the learnings that you hope to capture in the not on nintedanib group versus the on nintedanib group?
Yeah, it's going to be really interesting. We really want to design the trial to reflect the real-world population, and so with PPF, many patients are not only sometimes on background oral nintedanib, but they're often on background immunosuppressants. So you hear about drugs like rituximab or mycophenolate pretty frequently in this population. Many of the historical studies that have been done in this space have excluded patients on those drugs. We're allowing patients to come in on those drugs, provided that while on those drugs, they're continuing to decline in their lung function. So that ensures that we're picking progressors to study. But it's going to be really interesting because this is going to be the first dataset where we're going to have effectively a real-world population. So we'll have patients with PPF that are newly diagnosed.
We'll have patients that may have tried and failed an oral, and then we will have patients that are on background, whether oral nintedanib or immunosuppressants. We're stratifying for that as well. So it should be a really interesting observation to understand for the first time what pirfenidone and nintedanib do together. So the inhaled pirfenidone on top of oral nintedanib
Got it.
Will be a really interesting observation that will help us think about our combo.
In terms of the population actively progressing on nintedanib.
Are there potential accelerated opportunities that are worth considering in terms of, if you study your program and show benefits on top of active therapy, are there other opportunities to consider?
It's a really interesting question. I think for sure there are. We're going to have to see what we learn, and the imaging will be really helpful here. But fibrosis doesn't just exist in these two disease states, right? A disease I think that our Chief Medical Officer, Howard, and I care a lot about and would love to study is a disease called chronic lung allograft dysfunction, also called bronchiolitis obliterans syndrome. It's yet another form of fibrosis that sets in after patients have had a lung transplant. There's literally nothing approved for that disease today. We also have diseases like, we call them ILA, interstitial lung abnormalities. That's essentially an earlier stage version of this disease, kind of beginning to develop. We think that might be another exciting opportunity as well. For sure there are other segments here.
I just this morning on the DeWitt drive-in heard about a fellow who was 47 years old. He had done three tours of duty in Iraq, died of essentially PF, lung exposure from these burn pits in the Middle East. There are all these populations of people that really have nothing today that we would love to try to find some solutions for.
I apologize.
It's okay. Got to cough.
There we go. Sorry about that for anybody.
No worries.
On the webcast. Let's talk about AP02.
Our IPF study, 12 weeks.
What a good
Thank you again.
Side talk convo tonight. Mineralys.
At 12 weeks, what is the opportunity for us to see directional change as early as 12 weeks?
It is really remarkable. You are talking about the nintedanib program now.
Yes.
If you go back in history, and if you were to look at the oral nintedanib program, both in phase II and in phase III, they actually saw remarkable separation of the doses as early as four to six weeks. By 12 weeks, it is definitive. Our view is that for the dose-ranging study in AP02, that really 12 weeks is enough to observe a difference between the doses and to really pick the right dose to be able to move forward into phase III. That was the reason for the 12-week design, just to do that proper dose-ranging that FDA is looking for, pick the right dose, and then move it quickly forward from there.
Okay, great.
Yeah.
In terms of where the study is being conducted
Yeah.
Just remind us where it's being conducted, and then the opportunity to kind of bring that quickly to the U.S.
Yeah, that one's being conducted ex-U.S., but in geographies where they have great clinical experts and great centers. Largely places like Canada is probably one of our biggest enrollers. Our Chief Medical Officer is Canadian, so that always helps. Go Canada. Europe as well, Australia, New Zealand, and then a couple other countries where we have some just really wonderful sites. Places like Argentina and Turkey.
Great.
Yeah.
Okay. Combination strategy.
Yeah.
We've talked about this.
Yeah.
If I can get through the question without coughing too much. The main, I think, dynamic that I'm interested in is this opportunity to become the new background therapy for all treatments.
Yep.
The comparison we've talked about is sort of Gilead, Truvada
And HIV.
Yep.
What do you see as the opportunity for additional combinations, whether it be your own combination
Yep.
Or combinations with other therapies?
That sounds great. Maybe I will tell you just a little bit about the market, but then I will ask Doug to comment since that will give him an opportunity to kind of weigh in on the combo strategy. Just the market that I get real excited about, so I told you earlier how few patients are being treated. OFEV is the most successful drug in the market right now. It is a $4 billion drug globally, but there is about 300,000 patients diagnosed with this disease just in the U.S. If we were to use the lowest brand pricing in the marketplace today, that is $150,000 per patient per year. That means the U.S. market size today is a $42 billion market. That just assumes everyone in the U.S. is taking one medicine, ignoring the potential for combos.
Another analog for you, pulmonary hypertension, which is a disease I know that you are familiar with, and I am sure many others. It is a market that is about one-tenth the size. There is 30,000 patients diagnosed. I think it is an $8 billion market today. I am not going to start to give you some crazy numbers, but as we think about combo strategy, which is again where we think the market will evolve towards, there is a big opportunity here for us commercially to really do meaningful good for patients and realize a fair return for our company. Do you want to talk about the strategy?
Yeah, so the vast majority of the programs in phase II or phase III are being studied on top of nintedanib and pirfenidone. We think it is really a rising tide lifts all boats, where we are rooting for novel mechanisms.
I think we are interested to see where the BMS program lands. We have studied the Tyvaso data and looking at the TETON 1 and 2 in terms of the efficacy benefit in combination with the programs, as opposed to the monotherapy, which I think fell short of statistical significance. I think it is really our strategy is to start with AP03, but that is not the end. It is really thinking about other mechanisms as the field evolves over the next five to seven years.
Right. Great. And maybe just talk a little bit about JASCAYD's launch.
Yeah.
I think in the context of seeing a product look like it's headed to $2 billion in just 12 months on the market.
Yep.
What does that speak to?
Yeah, I think it's really interesting when we saw the initial data around this time, or the approval around this time last year, looking at comparable efficacy, maybe one would argue a touch below the two other orals. And then the tolerability profile was an incremental step, kind of a modest step forward. Still with diarrhea as the main liability with that. So very eager to see that and really impressed with the adoption and the uptake, and it really speaks to really improving tolerability is the most important attribute. Of course, there's a benchmark to efficacy. And I think even with the efficacy that's been seen with the orals, it's really the inability to retain on the medicine to benefit from the efficacy. So we're seeing wide adoption, surprising to some extent that it's not completely cannibalizing oral nintedanib.
I think it really speaks to what we are hearing from KOLs in terms of earlier frontline use, perhaps a soft step edit. Important to note that JASCAYD was priced at around $200,000 per annual course of cost of therapy. So, a meaningful premium to the previous branded oral prices, so establishing a new benchmark. We know that Tyvaso, different indication, but it is priced at $300,000. So, these soft step edits we are hearing from various plans is not rate-limiting. I think that the main difference in this category is that patients are cycling off the orals pretty quickly. So, the step edit in some categories can be more debilitating versus what we are seeing with JASCAYD.
Of course, it is growing the market, which I think really is not surprising given how much the pent-up demand from the patients that have cycled off the orals and were really looking for a novel therapy. But just as a reminder, it has been since 2014 that there has been innovation in approved therapies.
Yeah, and I just think to add to that, again, the orals are impossible to tolerate from a diarrhea and GI perspective. JASCAYD's number one liability is also diarrhea. So, the clinical data that they have on the combination looks quite good, but in the real world, being able to keep someone on combination oral medicine with any of these three orals is going to be really difficult. So that is where we come in, right? If we can solve the tolerability with inhaled delivery, it will allow the patients in a real-world setting to actually now step up to combos, which is why I think what the market needs.
Yeah. Then maybe just to wrap up, intellectual property and sort of cash on the balance sheet. What do you have in terms of cash runway, but also intellectual property, the opportunity, and how you sort of tie it together? I know that is a longer story.
You asked me that with 30 seconds left.
I know. Sorry about that.
Okay, I'm going to do my best.
Red team, go.
We have IP on the drug out to the 2040s. We have IP on the device to the 2040s. We have drug device combo patents, same. There is an FDA pathway. It is almost impossible to get a generic inhaled product approved because they are different. You can imagine, like the deposition pattern and the flow rate different. Generic companies have to redo the entire clinical program to get an approval. No one can access our device because we have a license and we have exclusivity to that device platform. Finally, commercial barriers. If someone were to get a branded copycat approved, because it is not a generic, they are not therapeutically substitutable. You have to commercialize them. Those products that do exist, they take a just slight discount on brand pricing, sort of like biosimilar.
It is this huge opportunity commercially to do a lot of good over a long-term horizon. Cash balance.
Yep. Cash takes us just around $400 million. That takes us into 2029 with the key assumption that our base case will be funding a phase III for AP01 and a phase III for AP02.
Fantastic. Thank you so much.
Thank you so much.
That was the most efficient IP rundown I think I have ever heard from anybody.
I am happy to spend more time on it with you in the future, but thanks for the time.
Awesome. Thank you so much.
Pleasure.